Tocimab

প্রাপ্তবয়স্ক:

Interruption of dosing may be needed for management of dose-related laboratory abnormalities including elevated liver enzymes, neutropenia, and thrombocytopenia.Rheumatoid Arthritis: Tocilizumab may be used as monotherapy or concomitantly with methotrexate or other non-biologic DMARDs as an intravenous infusion.Recommended Intravenous Dosage Regimen: The recommended dosage of Tocilizumab for adult patients given as a 60-minute single intravenous drip infusion is 4 mg per kg of body weight every 4 weeks followed by an increase to 8 mg per kg of body weight every 4 weeks based on clinical response. Reduction of dose from 8 mg per kg of body weight to 4 mg per kg of body weight is recommended for management of certain dose-related laboratory changes including elevated liver enzymes, neutropenia, and thrombocytopenia Doses exceeding 800 mg per infusion are not recommended in RA patients Polyarticular Juvenile Idiopathic Arthritis: Tocilizumab may be used as an intravenous infusion or as asubcutaneous injection alone or in combination with methotrexate. Do not change dose based solely on a single body weight measurement, as weight may fluctuate.Recommended Intravenous Dosage Regimen: The recommended dosage of Tocilizumab for PJIA patients given once every 4 weeks as a 60-minute single intravenous drip infusion is: Patients less than 30 kg weight: 10 mg per kg of body weight Patients at or above 30 kg weight: 8 mg per kg of body weight Systemic Juvenile Idiopathic Arthritis: Tocilizumab may be used as an intravenous infusion or as a subcutaneous injection alone or in combination with methotrexate. Do not change a dose based solely on a single body weight measurement, as weight may fluctuate.Recommended Intravenous Dosage Regimen: The recommended dose of Tocilizumab for SJIA patients givenonce every 2 weeks as a 60-minute single intravenous drip infusion is: Patients less than 30 kg weight: 12 mg per kg of body weight Patients at or above 30 kg weight: 8 mg per kg of body weight Coronavirus Disease 2019: The recommended dosage of Tocilizumab is a single 60-minuteintravenous infusion as follows: Patients less than 30 kg weight: 12 mg per kg of body weight Patients at or above 30 kg weight: 8 mg per kg of body weight If clinical signs or symptoms worsen or do not improve after the first dose, one additional infusion of Tocilizumab may be administered at least 8 hours after the initial infusion. Maximum dosage in COVID-19 patients is 800 mg per infusion. Cytokine Release Syndrome: Use only the intravenous route for treatment of CRS. The recommended dose of Tocilizumab for treatment of CRS given as a 60-minute intravenous infusion is:Recommended Intravenous CRS Dosage Patients less than 30 kg weight: 12 mg per kg of body weight Alone or in combination with corticosteroids. Patients at or above 30 kg weight: 8 mg per kg of body weight Alone or in combination with corticosteroids. If no clinical improvement in the signs and symptoms of CRS occurs after the first dose, up to 3 additional doses of Tocilizumab may be administered. The interval between consecutive doses should be at least 8 hours. Doses exceeding 800 mg per infusion are not recommended in CRS patients.Giant Cell Arteritis: The recommended dosage of Tocilizumab for adult patients given as a 60-minute single intravenous drip infusion is 6 mg per kg of body weight every 4 weeks in combination with a tapering course of glucocorticoids. Tocilizumab can be used alone following discontinuation of glucocorticoids Doses exceeding 600 mg per infusion are not recommended in GCA patients Systemic Sclerosis-Associated Interstitial Lung Disease: The recommended dose of Tocilizumab for adult patients with SSc-ILD is 162 mg given once every week as a subcutaneous injection. Intravenous administration is not approved for SSc-ILD Administration of Intravenous Formulation: For adults with RA, GCA, CRS, PJIA and SJIA patients at or above 30 kg, dilute to 100 mL in 0.9% or 0.45% Sodium Chloride Injection, USP for intravenous infusion using aseptic technique For PJIA, SJIA and CRS patients less than 30 kg, dilute to 50 mL in 0.9% or 0.45% Sodium Chloride Injection, USP for intravenous infusion using aseptic technique Administer as a single intravenous drip infusion over 1 hour; do not administer as bolus or push.